Immunogenicity assessment during the development of protein therapeutics
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunogenicity assessment during the development of protein therapeutics
Authors
Keywords
-
Journal
JOURNAL OF PHARMACY AND PHARMACOLOGY
Volume 70, Issue 5, Pages 584-594
Publisher
Wiley
Online
2017-09-05
DOI
10.1111/jphp.12810
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assay
- (2017) Heidi S. Schultz et al. PLoS One
- Immunology by numbers: quantitation of antigen presentation completes the quantitative milieu of systems immunology!
- (2016) Anthony W Purcell et al. CURRENT OPINION IN IMMUNOLOGY
- Peginesatide for the treatment of anemia due to chronic kidney disease – an unfulfilled promise
- (2016) Terhi Hermanson et al. Expert Opinion On Drug Safety
- TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity
- (2016) J. Mahlangu et al. HAEMOPHILIA
- Subvisible Particle Content, Formulation, and Dose of an Erythropoietin Peptide Mimetic Product Are Associated With Severe Adverse Postmarketing Events
- (2016) Joseph Kotarek et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Immunogenicity assessment of biotherapeutic products: An overview of assays and their utility
- (2015) Meenu Wadhwa et al. BIOLOGICALS
- Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin A
- (2015) Ronit Mazor et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity
- (2015) J. N. Mahlangu et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Fc fusion as a platform technology: potential for modulating immunogenicity
- (2015) Ditza Levin et al. TRENDS IN BIOTECHNOLOGY
- Immunodominance of CD4 T Cells to Foreign Antigens Is Peptide Intrinsic and Independent of Molecular Context: Implications for Vaccine Design
- (2014) J. M. Weaver et al. JOURNAL OF IMMUNOLOGY
- Biopharmaceutical benchmarks 2014
- (2014) Gary Walsh NATURE BIOTECHNOLOGY
- A Mathematical Model of the Effect of Immunogenicity on Therapeutic Protein Pharmacokinetics
- (2013) Xiaoying Chen et al. AAPS Journal
- T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation
- (2013) Vibha Jawa et al. CLINICAL IMMUNOLOGY
- Three deaths sink Affymax
- (2013) Laura DeFrancesco NATURE BIOTECHNOLOGY
- Building better drugs: developing and regulating engineered therapeutic proteins
- (2013) Chava Kimchi-Sarfaty et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Polymorphisms in the F8 Gene and MHC-II Variants as Risk Factors for the Development of Inhibitory Anti-Factor VIII Antibodies during the Treatment of Hemophilia A: A Computational Assessment
- (2013) Gouri Shankar Pandey et al. PLoS Computational Biology
- The Utility of Modeling and Simulation Approaches to Evaluate Immunogenicity Effect on the Therapeutic Protein Pharmacokinetics
- (2012) Juan Jose Perez Ruixo et al. AAPS Journal
- F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis
- (2012) S. C. Gouw et al. BLOOD
- Managing uncertainty: A perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins
- (2012) Amy S. Rosenberg et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Affymax poised to challenge Amgen
- (2012) Nuala Moran NATURE BIOTECHNOLOGY
- Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes
- (2012) W. Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
- (2011) Geertje M. Bartelds JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Development of Immune-Specific Interaction Potentials and Their Application in the Multi-Agent-System VaccImm
- (2011) Anna Lena Woelke et al. PLoS One
- Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics
- (2010) Danika Wullner et al. CLINICAL IMMUNOLOGY
- Methods to measure T-cell responses
- (2010) Magdalena Plebanski et al. Expert Review of Vaccines
- Biopharmaceutical benchmarks 2010
- (2010) Gary Walsh NATURE BIOTECHNOLOGY
- Control systems and decision making for antibody production
- (2010) Christopher C Goodnow et al. NATURE IMMUNOLOGY
- ImmunoGrid: towards agent-based simulations of the human immune system at a natural scale
- (2010) M. Halling-Brown et al. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY A-MATHEMATICAL PHYSICAL AND ENGINEERING SCIENCES
- Conditional modeling of antibody titers using a zero-inflated poisson random effects model: application to Fabrazyme®
- (2009) Peter L. Bonate et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates
- (2008) A DEGROOT et al. CURRENT OPINION IN PHARMACOLOGY
- Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment
- (2008) Jinhai Wang et al. NATURE BIOTECHNOLOGY
- Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
- (2008) Christine H. Chung et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Systematic Assessment of MHC Class II Peptide Binding Predictions and Evaluation of a Consensus Approach
- (2008) Peng Wang et al. PLoS Computational Biology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now